JP2023515199A - 免疫応答を調節するための材料及び方法 - Google Patents

免疫応答を調節するための材料及び方法 Download PDF

Info

Publication number
JP2023515199A
JP2023515199A JP2022551584A JP2022551584A JP2023515199A JP 2023515199 A JP2023515199 A JP 2023515199A JP 2022551584 A JP2022551584 A JP 2022551584A JP 2022551584 A JP2022551584 A JP 2022551584A JP 2023515199 A JP2023515199 A JP 2023515199A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
cdr2
trgv9
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515199A5 (https=
Inventor
ガネサン，ラジクマール
グレワル，イクバル，エス．
シン，サンジャヤ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/en
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023515199A publication Critical patent/JP2023515199A/ja
Publication of JP2023515199A5 publication Critical patent/JP2023515199A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022551584A 2020-02-27 2021-02-26 免疫応答を調節するための材料及び方法 Pending JP2023515199A (ja)

Applications Claiming Priority (91)

Application Number Priority Date Filing Date Title
US202062982574P 2020-02-27 2020-02-27
US202062982478P 2020-02-27 2020-02-27
US202062982664P 2020-02-27 2020-02-27
US202062982469P 2020-02-27 2020-02-27
US202062982374P 2020-02-27 2020-02-27
US202062982669P 2020-02-27 2020-02-27
US202062982525P 2020-02-27 2020-02-27
US202062982505P 2020-02-27 2020-02-27
US202062982462P 2020-02-27 2020-02-27
US202062982591P 2020-02-27 2020-02-27
US202062982602P 2020-02-27 2020-02-27
US202062982535P 2020-02-27 2020-02-27
US202062982492P 2020-02-27 2020-02-27
US202062982548P 2020-02-27 2020-02-27
US62/982,602 2020-02-27
US62/982,574 2020-02-27
US62/982,669 2020-02-27
US62/982,525 2020-02-27
US62/982,664 2020-02-27
US62/982,478 2020-02-27
US62/982,535 2020-02-27
US62/982,374 2020-02-27
US62/982,591 2020-02-27
US62/982,469 2020-02-27
US62/982,492 2020-02-27
US62/982,505 2020-02-27
US62/982,548 2020-02-27
US62/982,462 2020-02-27
US202062989027P 2020-03-13 2020-03-13
US202062989036P 2020-03-13 2020-03-13
US202062989006P 2020-03-13 2020-03-13
US202062989052P 2020-03-13 2020-03-13
US202062989075P 2020-03-13 2020-03-13
US202062989010P 2020-03-13 2020-03-13
US202062988996P 2020-03-13 2020-03-13
US202062989057P 2020-03-13 2020-03-13
US202062989042P 2020-03-13 2020-03-13
US202062989002P 2020-03-13 2020-03-13
US202062989024P 2020-03-13 2020-03-13
US202062989045P 2020-03-13 2020-03-13
US202062989068P 2020-03-13 2020-03-13
US202062989018P 2020-03-13 2020-03-13
US62/989,010 2020-03-13
US62/989,027 2020-03-13
US62/989,042 2020-03-13
US62/989,036 2020-03-13
US62/989,075 2020-03-13
US62/989,006 2020-03-13
US62/988,996 2020-03-13
US62/989,057 2020-03-13
US62/989,052 2020-03-13
US62/989,002 2020-03-13
US62/989,018 2020-03-13
US62/989,045 2020-03-13
US62/989,068 2020-03-13
US62/989,024 2020-03-13
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity
USPCT/US2020/031749 2020-05-07
US202063074839P 2020-09-04 2020-09-04
US202063074946P 2020-09-04 2020-09-04
US202063074749P 2020-09-04 2020-09-04
US202063074759P 2020-09-04 2020-09-04
US202063074854P 2020-09-04 2020-09-04
US202063074676P 2020-09-04 2020-09-04
US202063074937P 2020-09-04 2020-09-04
US202063074925P 2020-09-04 2020-09-04
US202063074962P 2020-09-04 2020-09-04
US202063074655P 2020-09-04 2020-09-04
US202063074735P 2020-09-04 2020-09-04
US202063074903P 2020-09-04 2020-09-04
US202063074700P 2020-09-04 2020-09-04
US202063074893P 2020-09-04 2020-09-04
US63/074,893 2020-09-04
US63/074,925 2020-09-04
US63/074,946 2020-09-04
US63/074,759 2020-09-04
US63/074,735 2020-09-04
US63/074,903 2020-09-04
US63/074,700 2020-09-04
US63/074,655 2020-09-04
US63/074,962 2020-09-04
US63/074,749 2020-09-04
US63/074,937 2020-09-04
US63/074,676 2020-09-04
US63/074,839 2020-09-04
US63/074,854 2020-09-04
US202063112462P 2020-11-11 2020-11-11
US202063112475P 2020-11-11 2020-11-11
US63/112,462 2020-11-11
US63/112,475 2020-11-11
PCT/US2021/019766 WO2021173896A1 (en) 2020-02-27 2021-02-26 Materials and methods for modulating an immune response

Publications (2)

Publication Number Publication Date
JP2023515199A true JP2023515199A (ja) 2023-04-12
JP2023515199A5 JP2023515199A5 (https=) 2024-03-06

Family

ID=77492135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551584A Pending JP2023515199A (ja) 2020-02-27 2021-02-26 免疫応答を調節するための材料及び方法

Country Status (10)

Country Link
US (1) US20220306739A1 (https=)
JP (1) JP2023515199A (https=)
KR (1) KR20220147631A (https=)
CN (1) CN115484981A (https=)
AU (1) AU2021225870A1 (https=)
CA (1) CA3173268A1 (https=)
IL (1) IL295897A (https=)
MX (1) MX2022010664A (https=)
TW (1) TW202144415A (https=)
WO (1) WO2021173896A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220690A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
MA55903A (fr) 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
CN115443150A (zh) 2019-12-17 2022-12-06 德克萨斯大学系统董事会 新型ddr1抗体和其用途
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
EP4237003A4 (en) 2020-10-28 2025-07-09 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
AU2023411024A1 (en) * 2022-12-23 2025-08-07 The Wistar Institute Of Anatomy And Biology Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
JP2022533538A (ja) * 2019-05-08 2022-07-25 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
CA3297793A1 (en) * 2016-12-26 2026-03-02 Kagoshima University Antibody which binds to myelin oligodendrocyte glycoprotein
EP3743081A4 (en) * 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3101271A1 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
JP2023517660A (ja) * 2020-03-13 2023-04-26 ヤンセン バイオテツク，インコーポレーテツド シグレック３／ｃｄ３３に結合させるための材料及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
JP2022533538A (ja) * 2019-05-08 2022-07-25 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 74, no. 5, JPN6025001820, 2014, pages 1349 - 1360, ISSN: 0005656658 *
CELL MOL IMMUNOL, vol. 12, JPN6025001821, 2015, pages 656 - 668, ISSN: 0005656659 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220690A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体

Also Published As

Publication number Publication date
IL295897A (en) 2022-10-01
MX2022010664A (es) 2022-11-30
US20220306739A1 (en) 2022-09-29
KR20220147631A (ko) 2022-11-03
WO2021173896A1 (en) 2021-09-02
AU2021225870A1 (en) 2022-10-20
WO2021173896A8 (en) 2022-10-06
TW202144415A (zh) 2021-12-01
CN115484981A (zh) 2022-12-16
CA3173268A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US20220306739A1 (en) Materials and methods for modulating an immune response
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
US20210284731A1 (en) Methods and materials for modulating an immune response
JP2021521784A (ja) ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
US20260103521A1 (en) Methods and Compositions for Modulating Beta Chain Mediated Immunity
JP2024506682A (ja) 抗ＴＣＲδ鎖可変部１抗体
US20260055185A1 (en) Materials and methods for modulating delta chain mediated immunity
EP4237003A1 (en) Compositions and methods for modulating delta gamma chain mediated immunity
WO2022056197A9 (en) Immune targeting molecules and uses thereof
KR20230083267A (ko) 다중특이적 항-tcr 델타 가변 1 항체
JP2024509332A (ja) 多重特異性抗ＴＣＲδ可変部１抗体
TW202342536A (zh) 多特異性抗ＴＣＲδ可變１抗體
EP4110390A1 (en) Materials and methods for modulating an immune response
HK40085531A (en) Materials and methods for modulating an immune response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210